Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H20N2O.ClH |
| Molecular Weight | 268.782 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(N1CCCC1)C(=O)NC2=CC=CC=C2C
InChI
InChIKey=JUSHHIAJHXVGRP-UHFFFAOYSA-N
InChI=1S/C14H20N2O.ClH/c1-11-7-3-4-8-13(11)15-14(17)12(2)16-9-5-6-10-16;/h3-4,7-8,12H,5-6,9-10H2,1-2H3,(H,15,17);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H20N2O |
| Molecular Weight | 232.3214 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/776194
Sources: https://www.ncbi.nlm.nih.gov/pubmed/776194
Aptocaine (Pirothesin, Pharmaceutical Manufacturing Company) is a new local anaesthetic agent, the first of note to be synthesized in Britain. It is related toprilocaine; like prilocaine, it has a low sub-cutaneous toxicity, but preliminary studies suggest that, unlike prilocaine, it does not induce methaemoglobinaemia. It has been found to produce satisfactory analgesia, of longer duration than lignocaine, by several routes, at a concentration of 3% in animals.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification of metabolites of aptocaine and some related compounds [proceedings]. | 1976-12 |
|
| Intradermal study of a new local anaesthetic agent aptocaine. | 1976-04 |
|
| [A new local anesthetic for dentistry: 1st study of aptocaine chlorhydrate in combination with corbadrine chlorhydrate]. | 1971-06-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/776194
In a double-blind trial in 28 human volunteers, a new local anaesthetic agent, aptocaine, was compared intradermally at 1, 2 and 3% concentrations with lignocaine 2% and bupivacaine 0.5%.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:03:34 GMT 2025
by
admin
on
Mon Mar 31 23:03:34 GMT 2025
|
| Record UNII |
N8QZQ3Y7GY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3084310
Created by
admin on Mon Mar 31 23:03:34 GMT 2025 , Edited by admin on Mon Mar 31 23:03:34 GMT 2025
|
PRIMARY | |||
|
DTXSID80940955
Created by
admin on Mon Mar 31 23:03:34 GMT 2025 , Edited by admin on Mon Mar 31 23:03:34 GMT 2025
|
PRIMARY | |||
|
N8QZQ3Y7GY
Created by
admin on Mon Mar 31 23:03:34 GMT 2025 , Edited by admin on Mon Mar 31 23:03:34 GMT 2025
|
PRIMARY | |||
|
242-933-8
Created by
admin on Mon Mar 31 23:03:34 GMT 2025 , Edited by admin on Mon Mar 31 23:03:34 GMT 2025
|
PRIMARY | |||
|
19281-32-4
Created by
admin on Mon Mar 31 23:03:34 GMT 2025 , Edited by admin on Mon Mar 31 23:03:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |